NovoCure Limited Q1 Earnings: Core Business Accelerating (NVCR)
Luis Alvarez/DigitalVision via Getty Images I am updating my previous analysis on NovoCure Limited (NASDAQ:NVCR) in light of Q1 2024 earnings which were released pre-market on Thursday, May 2nd. I previously rated NovoCure a buy for the following reasons: Core business was very healthy with growing revenue and a 75% gross margin. NovoCure was pursuing…